ES2286404T3 - Oxa-y tiadiazoles y su uso como inhibidores de metaloproteinasa. - Google Patents

Oxa-y tiadiazoles y su uso como inhibidores de metaloproteinasa. Download PDF

Info

Publication number
ES2286404T3
ES2286404T3 ES03702791T ES03702791T ES2286404T3 ES 2286404 T3 ES2286404 T3 ES 2286404T3 ES 03702791 T ES03702791 T ES 03702791T ES 03702791 T ES03702791 T ES 03702791T ES 2286404 T3 ES2286404 T3 ES 2286404T3
Authority
ES
Spain
Prior art keywords
alkyl
quad
group
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03702791T
Other languages
English (en)
Spanish (es)
Inventor
A.P. British Biotech Pharmaceuticals Ltd Ayscough
S.J. British Biotech Pharmaceuticals ltd DAVIES
Gilles British Biotech Pharmaceuticals Ltd PAIN
Jean-Yves Gillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Vernalis R&D Ltd
Serono Laboratories UK Ltd
Original Assignee
Laboratoires Serono SA
Vernalis R&D Ltd
Serono Laboratories UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA, Vernalis R&D Ltd, Serono Laboratories UK Ltd filed Critical Laboratoires Serono SA
Application granted granted Critical
Publication of ES2286404T3 publication Critical patent/ES2286404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES03702791T 2002-02-22 2003-02-20 Oxa-y tiadiazoles y su uso como inhibidores de metaloproteinasa. Expired - Lifetime ES2286404T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0204159.8A GB0204159D0 (en) 2002-02-22 2002-02-22 Metalloproteinase inhibitors
GB0204159 2002-02-22

Publications (1)

Publication Number Publication Date
ES2286404T3 true ES2286404T3 (es) 2007-12-01

Family

ID=9931543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03702791T Expired - Lifetime ES2286404T3 (es) 2002-02-22 2003-02-20 Oxa-y tiadiazoles y su uso como inhibidores de metaloproteinasa.

Country Status (26)

Country Link
US (4) US7358265B2 (de)
EP (1) EP1476438B1 (de)
JP (1) JP4615864B2 (de)
KR (1) KR101098614B1 (de)
CN (1) CN100351245C (de)
AT (1) ATE360007T1 (de)
AU (1) AU2003205910B2 (de)
BR (1) BR0307899A (de)
CA (1) CA2475867C (de)
CY (1) CY1106730T1 (de)
DE (1) DE60313292T2 (de)
DK (1) DK1476438T3 (de)
EA (1) EA007609B1 (de)
ES (1) ES2286404T3 (de)
GB (1) GB0204159D0 (de)
HR (1) HRP20040725A2 (de)
IL (1) IL163413A (de)
MX (1) MXPA04008132A (de)
NO (1) NO330772B1 (de)
PL (1) PL210773B1 (de)
PT (1) PT1476438E (de)
RS (1) RS51354B (de)
SI (1) SI1476438T1 (de)
UA (1) UA78275C2 (de)
WO (1) WO2003070711A1 (de)
ZA (1) ZA200406755B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101537A1 (en) * 2003-05-17 2004-11-25 British Biotech Pharmaceuticals Ltd Metalloproteinase inhibitors
PL1660471T3 (pl) 2003-08-23 2011-10-31 Vernalis R&D Ltd Pochodne kwasu hydroksamowego jako inhibitory metaloproteinaz
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
ATE537164T1 (de) 2004-12-21 2011-12-15 Merck Serono Sa Zyklische sulfonylaminoderivate und deren verwendung als mmp-hemmer
ATE516279T1 (de) 2005-01-31 2011-07-15 Merck Serono Sa N-hydroxyamidderivate und ihre verwendung
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
EP1933860A2 (de) 2005-09-01 2008-06-25 Ares Trading S.A. Behandlung von optikusneuritis
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
EA201791621A1 (ru) * 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
CN105384736B (zh) * 2015-10-28 2018-11-02 南昌大学 一种ⅳ型胶原酶抑制剂及合成方法
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
AU2018348350B2 (en) 2017-10-11 2024-05-02 Aurigene Oncology Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2020004531A (es) 2017-11-03 2020-08-03 Aurigene Discovery Tech Ltd Inhibidores dobles de tim-3 y las vias de pd-1.
EP3706798A1 (de) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Gemeinsame therapien zur immunmodulation
CN108530378B (zh) * 2018-05-29 2021-09-14 济南大学 一类含有噁二唑结构的氮原子双取代异羟肟酸类化合物、用途及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404046D0 (en) 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
US5665753A (en) * 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
BR9714142A (pt) * 1996-12-17 2000-02-29 Warner Lambert Co Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas
WO1999047529A1 (en) * 1998-03-18 1999-09-23 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
JP2001031637A (ja) * 1999-05-17 2001-02-06 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy

Also Published As

Publication number Publication date
US20100035943A1 (en) 2010-02-11
IL163413A (en) 2010-11-30
EA200401095A1 (ru) 2005-02-24
AU2003205910A1 (en) 2003-09-09
JP2005522455A (ja) 2005-07-28
KR101098614B1 (ko) 2011-12-23
ATE360007T1 (de) 2007-05-15
PT1476438E (pt) 2007-07-25
AU2003205910B2 (en) 2008-12-04
CN100351245C (zh) 2007-11-28
US20050222189A1 (en) 2005-10-06
YU71604A (sh) 2006-08-17
CA2475867A1 (en) 2003-08-28
NO20043846L (no) 2004-09-14
DE60313292T2 (de) 2007-12-27
DE60313292D1 (de) 2007-05-31
EP1476438A1 (de) 2004-11-17
EP1476438B1 (de) 2007-04-18
EA007609B1 (ru) 2006-12-29
GB0204159D0 (en) 2002-04-10
HK1078583A1 (zh) 2006-03-17
BR0307899A (pt) 2004-12-07
CA2475867C (en) 2011-07-05
NO330772B1 (no) 2011-07-11
DK1476438T3 (da) 2007-08-20
WO2003070711A1 (en) 2003-08-28
KR20040101232A (ko) 2004-12-02
US7358265B2 (en) 2008-04-15
PL210773B1 (pl) 2012-02-29
US20080227833A1 (en) 2008-09-18
UA78275C2 (en) 2007-03-15
CY1106730T1 (el) 2012-10-24
US20110086893A1 (en) 2011-04-14
SI1476438T1 (sl) 2007-10-31
JP4615864B2 (ja) 2011-01-19
CN1646505A (zh) 2005-07-27
RS51354B (sr) 2011-02-28
MXPA04008132A (es) 2005-06-17
ZA200406755B (en) 2006-07-26
PL372268A1 (en) 2005-07-11
HRP20040725A2 (en) 2005-04-30

Similar Documents

Publication Publication Date Title
US20080227833A1 (en) Oxa- and thiadiazoles and their use as metalloproteinase inhibitors
ES2358426T3 (es) Compuestos para la inflamación y usos inmunorrelacionados.
CA2634198C (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
ES2231965T3 (es) Inhibidores de metaloproteinasas de matriz.
ES2218156T3 (es) Ureas y su uso como moduladores de la adhesion celular.
ES2302033T3 (es) Derivados de quinozalina como inhibidores de la elastasa de los neurofilos y su utilizacion.
ES2467097T3 (es) Compuesto de sulfonamida o sal del mismo
EA009051B1 (ru) О-замещенные гидроксиарильные производные
JPWO2008123207A1 (ja) オルニチン誘導体
EP1525193B1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
KR20020019971A (ko) 항균제
ES2448394T3 (es) Derivados sustituidos de benzotiazol y benzoxazol útiles como inhibidores de la DPP-1.
JP2010531873A (ja) Ｈｓｐ誘導剤としての新規の置換ピペリドン
US6258851B1 (en) Metalloproteinase inhibitors
JP4550353B2 (ja) 造血器型プロスタグランジンｄ２合成酵素阻害剤
WO1998023588A9 (en) Metalloproteinase inhibitors
EP0944597A1 (de) Metalloproteinase-hemmer
ES2544104T3 (es) Derivados de bifenilo útiles como antagonistas del receptor glucagón
WO2004101537A1 (en) Metalloproteinase inhibitors
US20070208021A1 (en) Phenoxyacetic Acid Derivatives and Drug Comprising The Same
ES2365731T3 (es) Derivados de ácido hidroxámico como inhibidores de metaloproteinasa.
JP2008303177A (ja) Ｐａｉ−１産生抑制作用を有する５−アルキル−５−フェニル−３−ピリダジノン誘導体